| Patient | George H. W. Bush |
|---|---|
| Date of birth | 1959-06-12 |
| Identifiers | MRN HR-ML018-SYN; SSN (made up) 000-18-7245 |
| Document date | 2026-11-01 |
| Author | Douglas Whitford, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Post-hospital visit for new atrial fibrillation, with thyroid tests showing hyperthyroidism. Concerns: New irregular heartbeat that began as unusual tiredness on a run; wants to know whether he can keep running; Wants to get back to a full working schedule and to exercise as soon as it is safe. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metoprolol succinate extended-release 50 mg oral tablet, one tablet by mouth daily (started in hospital) | One tablet each morning | Oral route | 2026-05-05 to 2026-07-17 | stopped | S |
| Metoprolol succinate extended-release 25 mg oral tablet, one tablet by mouth daily (taper) | One tablet each morning for eight weeks, then stop | Oral route | 2026-07-17 to 2026-09-11 | stopped | S |
| Apixaban 5 mg oral tablet, one tablet by mouth twice daily (started in hospital) | One tablet twice daily | Oral route | 2026-05-05 to 2026-09-11 | stopped | S |
| Methimazole 10 mg oral tablet, two tablets (20 mg) by mouth daily | Two tablets once daily; stop three days before radioactive iodine | Oral route | 2026-05-08 to 2026-05-26 | completed | S |
| Levothyroxine 75 mcg oral tablet, one tablet by mouth daily before breakfast | One tablet on an empty stomach 30 to 60 minutes before breakfast | Oral route | 2026-07-17 to 2026-09-11 | stopped | S |
| Levothyroxine 100 mcg oral tablet, one tablet by mouth daily before breakfast | One tablet on an empty stomach 30 to 60 minutes before breakfast | Oral route | 2026-09-11 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Transthoracic echocardiogram in hospital: normal chamber sizes, including the left atrium, normal valves, and left ventricular ejection fraction 60 percent | 2026-05-05 to 2026-05-05 | completed | S |
| 12-lead ECG at intake: sinus rhythm at 88 per minute, normal intervals, no ischemic change | 2026-05-08 to 2026-05-08 | completed | S |
| Radioactive iodine (iodine-131, 15 mCi by mouth) for Graves' disease, with written radiation-safety instructions | 2026-05-29 to 2026-05-29 | completed | S |
| 14-day ambulatory ECG patch: sinus rhythm throughout, no atrial fibrillation or flutter, rare atrial ectopic beats | 2026-08-24 to 2026-09-07 | completed | S |
| Advance care planning conversation, about 20 minutes | 2026-10-16 to 2026-10-16 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2025-10-14 | High-dose influenza vaccine, 2025-2026 season | completed | S |
| 2024-10-08 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2022-03-15 | Recombinant zoster vaccine, two-dose series completed | completed | S |
| 2026-10-16 | High-dose influenza vaccine, 2026-2027 season | completed | S |
| 2026-10-16 | Tdap vaccine | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| May 4, 1991 | Atrial fibrillation that began as unusual fatigue while running; hospital stay of two days, with normal ECG apart from the rhythm and a normal cardiac ultrasound; sinus rhythm restored on medication without cardioversion | D (CLM-0002, CLM-0003, CLM-0004) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| New irregular heartbeat that began as unusual tiredness on a run; wants to know whether he can keep running | active | S |
| Wants to get back to a full working schedule and to exercise as soon as it is safe | active | S |
Most recent measures: Thyrotropin [Units/volume] in Serum or Plasma 2.6 on 2026-10-16; Thyroxine (T4) free [Mass/volume] in Serum or Plasma 0.9 on 2026-09-11; Triiodothyronine (T3) [Mass/volume] in Serum or Plasma 78 on 2026-07-17; Thyrotropin receptor Ab [Units/volume] in Serum 8.2 on 2026-05-08; Leukocytes [#/volume] in Blood by Automated count 6.8 on 2026-05-08; Neutrophils [#/volume] in Blood by Automated count 3.5 on 2026-05-20; Hemoglobin [Mass/volume] in Blood 14.8 on 2026-05-08; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 30 on 2026-05-20; Creatinine [Mass/volume] in Serum or Plasma 0.92 on 2026-05-08; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 87 on 2026-05-08; Potassium [Moles/volume] in Serum or Plasma 4.2 on 2026-05-08; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-10-16; Total score [Mini-Cog] 5 on 2026-10-16; Total score [AUDIT-C] 1 on 2026-10-16; Cholesterol [Mass/volume] in Serum or Plasma 186 on 2026-10-16; Cholesterol in HDL [Mass/volume] in Serum or Plasma 58 on 2026-10-16; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 108 on 2026-10-16; Triglyceride [Mass/volume] in Serum or Plasma 100 on 2026-10-16; Hemoglobin A1c/Hemoglobin.total in Blood 5.4 on 2026-10-16 [S]
Strengths and supports: Supports: spouse, adult children, and close colleagues and friends [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Paroxysmal atrial fibrillation, first detected four days before intake while running, triggered by hyperthyroidism; CHA2DS2-VASc 1; synthetic modern episode linked to his documented atrial fibrillation | active | confirmed | I48.0 | S — Synthetic modern classification of a documented arrhythmia. |
| Graves' disease with hyperthyroidism; synthetic modern diagnosis linked to his documented Graves' disease | active | confirmed | E05.00 | S — Synthetic modern diagnosis confirmed by thyroid tests and TSH receptor antibody; the historical diagnosis is D. |
| Hypothyroidism after radioactive iodine, on levothyroxine replacement | active | confirmed | E89.0 | S — Synthetic modern diagnosis linked to his documented hypothyroidism and lifelong thyroid hormone. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-08 | Thyrotropin [Units/volume] in Serum or Plasma | 0.005 | m[IU]/L | 0.4-4 mIU/L | Low | S |
| 2026-05-08 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 3.6 | ng/dL | 0.8-1.8 ng/dL | High | S |
| 2026-05-08 | Triiodothyronine (T3) [Mass/volume] in Serum or Plasma | 280 | ng/dL | 80-200 ng/dL | High | S |
| 2026-05-08 | Thyrotropin receptor Ab [Units/volume] in Serum | 8.2 | [IU]/L | <=1.75 [IU]/L | High | S |
| 2026-05-08 | Leukocytes [#/volume] in Blood by Automated count | 6.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-05-08 | Neutrophils [#/volume] in Blood by Automated count | 3.9 | 10*3/uL | 1.5-7.5 10*3/uL | Normal | S |
| 2026-05-08 | Hemoglobin [Mass/volume] in Blood | 14.8 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2026-05-08 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 32 | U/L | 7-55 U/L | Normal | S |
| 2026-05-08 | Creatinine [Mass/volume] in Serum or Plasma | 0.92 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 2026-05-08 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 87 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-08 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-05-20 | Thyrotropin [Units/volume] in Serum or Plasma | 0.01 | m[IU]/L | 0.4-4 mIU/L | Low | S |
| 2026-05-20 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 2.2 | ng/dL | 0.8-1.8 ng/dL | High | S |
| 2026-05-20 | Triiodothyronine (T3) [Mass/volume] in Serum or Plasma | 176 | ng/dL | 80-200 ng/dL | Normal | S |
| 2026-05-20 | Neutrophils [#/volume] in Blood by Automated count | 3.5 | 10*3/uL | 1.5-7.5 10*3/uL | Normal | S |
| 2026-05-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 | U/L | 7-55 U/L | Normal | S |
| 2026-07-17 | Thyrotropin [Units/volume] in Serum or Plasma | 5.6 | m[IU]/L | 0.4-4 mIU/L | High | S |
| 2026-07-17 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 0.6 | ng/dL | 0.8-1.8 ng/dL | Low | S |
| 2026-07-17 | Triiodothyronine (T3) [Mass/volume] in Serum or Plasma | 78 | ng/dL | 80-200 ng/dL | Low | S |
| 2026-09-11 | Thyrotropin [Units/volume] in Serum or Plasma | 6.4 | m[IU]/L | 0.4-4 mIU/L | High | S |
| 2026-09-11 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 0.9 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2026-10-16 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-10-16 | Total score [Mini-Cog] | 5 | {score} | S | ||
| 2026-10-16 | Total score [AUDIT-C] | 1 | {score} | S | ||
| 2026-10-16 | Thyrotropin [Units/volume] in Serum or Plasma | 2.6 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 2026-10-16 | Cholesterol [Mass/volume] in Serum or Plasma | 186 | mg/dL | <=200 mg/dL | Normal | S |
| 2026-10-16 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 58 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-10-16 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 108 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-10-16 | Triglyceride [Mass/volume] in Serum or Plasma | 100 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-10-16 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.4 | % | <=5.6% | Normal | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-08 | Body height | 188 | cm | S |
| 2026-05-08 | Body weight | 86 | kg | S |
| 2026-05-08 | Body mass index (BMI) [Ratio] | 24.3 | kg/m2 | S |
| 2026-05-08 | Systolic blood pressure | 142 | mm[Hg] | S |
| 2026-05-08 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-05-08 | Heart rate | 88 | /min | S |
| 2026-05-08 | Respiratory rate | 16 | /min | S |
| 2026-05-08 | Body temperature | 37.1 | Cel | S |
| 2026-05-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-05-20 | Body height | 188 | cm | S |
| 2026-05-20 | Body weight | 86.4 | kg | S |
| 2026-05-20 | Body mass index (BMI) [Ratio] | 24.4 | kg/m2 | S |
| 2026-05-20 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-05-20 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-05-20 | Heart rate | 72 | /min | S |
| 2026-05-20 | Respiratory rate | 14 | /min | S |
| 2026-05-20 | Body temperature | 36.9 | Cel | S |
| 2026-05-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-07-17 | Body height | 188 | cm | S |
| 2026-07-17 | Body weight | 88.6 | kg | S |
| 2026-07-17 | Body mass index (BMI) [Ratio] | 25.1 | kg/m2 | S |
| 2026-07-17 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-07-17 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-07-17 | Heart rate | 64 | /min | S |
| 2026-07-17 | Respiratory rate | 14 | /min | S |
| 2026-07-17 | Body temperature | 36.6 | Cel | S |
| 2026-07-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-09-11 | Body height | 188 | cm | S |
| 2026-09-11 | Body weight | 90.2 | kg | S |
| 2026-09-11 | Body mass index (BMI) [Ratio] | 25.5 | kg/m2 | S |
| 2026-09-11 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-09-11 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-09-11 | Heart rate | 62 | /min | S |
| 2026-09-11 | Respiratory rate | 14 | /min | S |
| 2026-09-11 | Body temperature | 36.6 | Cel | S |
| 2026-09-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-10-16 | Body height | 188 | cm | S |
| 2026-10-16 | Body weight | 90.8 | kg | S |
| 2026-10-16 | Body mass index (BMI) [Ratio] | 25.7 | kg/m2 | S |
| 2026-10-16 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-10-16 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-10-16 | Heart rate | 68 | /min | S |
| 2026-10-16 | Respiratory rate | 14 | /min | S |
| 2026-10-16 | Body temperature | 36.7 | Cel | S |
| 2026-10-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-05-08 | Post-hospital visit for new atrial fibrillation, with thyroid tests showing hyperthyroidism | finished | S |
| 2026-05-20 | Two-week review on methimazole, with endocrinology consultation | finished | S |
| 2026-07-17 | Seven-week review after radioactive iodine | finished | S |
| 2026-09-11 | Four-month review: levothyroxine titration and anticoagulation decision | finished | S |
| 2026-10-16 | Subsequent annual wellness visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Rate control with metoprolol succinate 50 mg daily; no antiarrhythmic drug or cardioversion while thyrotoxic, because most thyrotoxic atrial fibrillation reverts once thyroid levels are normal; taper the beta-blocker once he is no longer thyrotoxic | completed | GL-ACC-AF-2023, GL-CMID-2026, GL-ATA-HYPER-2016 | S |
| Stroke-risk and bleeding-risk scoring (CHA2DS2-VASc 1 for age 65 to 74; HAS-BLED 1 for age over 65) with a shared decision to continue apixaban 5 mg twice daily while thyrotoxic, then reassess once sustained sinus rhythm is confirmed after he is no longer thyrotoxic | completed | GL-ACC-AF-2023, GL-CMID-2026 | S |
| Methimazole 20 mg daily after a baseline blood count and liver tests, with written advice to stop it and call at once for fever, sore throat, mouth ulcers, jaundice, or dark urine; stop three days before radioactive iodine | completed | GL-ATA-HYPER-2016 | S |
| Endocrinology consultation to confirm Graves' disease, assess the eyes, and choose definitive treatment (radioactive iodine, long-term methimazole, or surgery) | completed | GL-ATA-HYPER-2016 | S |
| After radioactive iodine: free T4 and total T3 within one to two months and then every four to six weeks until stable; levothyroxine once hypothyroid, started below full replacement; TSH four to eight weeks after each dose change, at six months once stable, then yearly; target TSH 0.4 to 4.0 mIU/L | completed | GL-ATA-HYPER-2016, GL-ATA-HYPO-2014, GL-CMID-2026 | S |
| Atrial fibrillation monitoring at every visit (heart rate and rhythm, blood pressure, weight, symptoms, activity, alcohol, tobacco), ECG when indicated, echocardiogram at diagnosis, CHA2DS2-VASc and HAS-BLED yearly, creatinine and blood count at baseline and yearly on apixaban, and sleep apnea screening at diagnosis and yearly | completed | GL-ACC-AF-2023, GL-CMID-2026 | S |
| Return to running in steps once the heart rate is controlled, aiming for about 210 minutes a week of moderate to vigorous activity; limit alcohol to no more than one drink a day | completed | GL-ACC-AF-2023, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Resting heart rate below 110 per minute without palpitations while thyrotoxic | 2026-05-20 | completed | Heart rate 72 in sinus rhythm on metoprolol two weeks after intake | S |
| No atrial fibrillation once no longer thyrotoxic, confirmed by ambulatory monitoring before the anticoagulation decision | 2026-09-11 | completed | Sinus rhythm throughout a 14-day ECG patch | S |
| TSH within 0.4 to 4.0 mIU/L on levothyroxine | 2026-10-16 | completed | TSH 6.4 on 75 mcg at the four-month review; 2.6 five weeks after the increase to 100 mcg | S |
| Back to running three miles several days a week without symptoms | 2026-09-11 | completed | Running three miles four days a week without palpitations | S |